Status:
COMPLETED
Darbepoetin Administration to Preterm Infants
Lead Sponsor:
University of New Mexico
Collaborating Sponsors:
Thrasher Research Fund
University of Colorado, Denver
Conditions:
Infant, Newborn
Eligibility:
All Genders
1-49 years
Phase:
PHASE2
Brief Summary
Infants born prematurely do not increase production of the primary red cell growth factor, erythropoietin (Epo), and often develop an anemia called the "anemia of prematurity." The anemia of prematuri...
Detailed Description
A novel erythropoiesis stimulating protein, Darbepoetin alfa (Darbepoetin) has been developed by Amgen Inc. and has been shown to be effective in increasing hematocrit using once weekly or once every ...
Eligibility Criteria
Inclusion
- 500-1250 grams birth weight
- less than or equal to 32 weeks gestation
- less than 2 days of age
Exclusion
- severe hemorrhagic disease
- severe hemolytic disease
- DIC
- seizures
- hypertension
- thromboses
- receiving erythropoietin
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00334737
Start Date
June 1 2006
End Date
June 1 2014
Last Update
February 4 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado
Denver, Colorado, United States, 80218
2
McKay-Dee Hospital
Ogden, Utah, United States, 84403
3
LDS Hospital
Salt Lake City, Utah, United States, 84103